(Q44599380)

English

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

scientific article published in July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec (English)

1 reference

Europe PubMed Central

4 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Stefan Korsatko

1

1 reference

Europe PubMed Central

4 December 2017

Sigrid Deller

2

1 reference

Europe PubMed Central

4 December 2017

Gerd Koehler

3

1 reference

Europe PubMed Central

4 December 2017

Julia K Mader

4

1 reference

Europe PubMed Central

4 December 2017

Katharina Neubauer

5

1 reference

Europe PubMed Central

4 December 2017

Charlotte L Adrian

6

1 reference

Europe PubMed Central

4 December 2017

Henrik Thomsen

7

1 reference

Europe PubMed Central

4 December 2017

Hanne Haahr

8

1 reference

Europe PubMed Central

4 December 2017

Thomas R Pieber

9

1 reference

Europe PubMed Central

4 December 2017

publication date

1 July 2013

1 reference

Europe PubMed Central

4 December 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

4 December 2017

33

1 reference

Europe PubMed Central

4 December 2017

7

1 reference

Europe PubMed Central

4 December 2017

515-521

1 reference

Europe PubMed Central

4 December 2017

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Insulin dose-response studies in severely insulin-resistant type 2 diabetes--evidence for effectiveness of very high insulin doses.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0096-7

21 January 2018

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0096-7

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44599380&oldid=2143940680"